From discovery to clinical validation, our pipeline is designed to deliver impact where it’s needed most.
Advancing a pipeline of therapies designed to address rare, underserved, and resistant conditions. Anchored in mechanistic science, durable IP, and smart clinical execution.
Advancing a pipeline of therapies designed to address rare, underserved, and resistant conditions. Anchored in mechanistic science, durable IP, and smart clinical execution.
Featured Programs
Featured Programs
MFW
Uveitis
Program: VT1953 Gel
Status: Clinical Development — Advancing toward pivotal Phase 3 development following positive Phase 2 results
Malignant fungating wounds affect approximately 5%-14% of advanced cancer patients worldwide, causing symptoms like severe malodor, pain, and social isolation. There are currently no FDA-approved therapies indicated for MFW symptoms—patients rely on suboptimal off-label treatments.
VT-1953 is a topical, dual-action therapy designed to address both the microbial and inflammatory drivers of malodor and pain associated with malignant fungating wounds.
• Dual mechanism: inhibits bacterial DNA gyrase and modulates MD2/TLR inflammatory signaling
• Phase 2 study met key malodor and patient-reported endpoints
• No FDA-approved treatment specifically addresses MFW symptoms
MFW
Uveitis
Program: VT1953 Gel
Status: Clinical Development — Advancing toward pivotal Phase 3 development following positive Phase 2 results
Malignant fungating wounds affect approximately 5%-14% of advanced cancer patients worldwide, causing symptoms like severe malodor, pain, and social isolation. There are currently no FDA-approved therapies indicated for MFW symptoms—patients rely on suboptimal off-label treatments.
VT-1953 is a topical, dual-action therapy designed to address both the microbial and inflammatory drivers of malodor and pain associated with malignant fungating wounds.
• Dual mechanism: inhibits bacterial DNA gyrase and modulates MD2/TLR inflammatory signaling
• Phase 2 study met key malodor and patient-reported endpoints
• No FDA-approved treatment specifically addresses MFW symptoms
A Cambridge, MA, based global healthcare platform synergizing biotech, medical devices, and AI.
Vyome Holdings, Inc.
Nasdaq: HIND
PRINCIPAL OFFICE
Harvard Square, One Mifflin Place, Suite 400, Cambridge, MA 02138
PHONE
+1 973-832-8147
SUBSIDIARIES
Vyome Therapeutics, Inc.
OFFICE
Harvard Square, One Mifflin Place, Suite 400, Cambridge, MA 02138
Vyome Therapeutics Limited, Subsidiary of Vyome Therapeutics, Inc.
OFFICE
Plot No. 465, Ground Floor, F.I.E., Patparganj Industrial Area, Delhi, India- 110092.
PHONE
+91-99682-17333
*Certain statements on this site are forward-looking within the meaning of federal securities laws. Please see our full disclaimer here.
Vyome Holdings, Inc.
Nasdaq: HIND
PRINCIPAL OFFICE
Harvard Square, One Mifflin Place, Suite 400, Cambridge, MA 02138
PHONE
+1 973-832-8147
SUBSIDIARIES
Vyome Therapeutics, Inc.
OFFICE
Harvard Square, One Mifflin Place, Suite 400, Cambridge, MA 02138
Vyome Therapeutics Limited, Subsidiary of Vyome Therapeutics, Inc.
OFFICE
Plot No. 465, Ground Floor, F.I.E., Patparganj Industrial Area, Delhi, India- 110092.
PHONE
+91-99682-17333
*Certain statements on this site are forward-looking within the meaning of federal securities laws. Please see our full disclaimer here.
A Cambridge, MA, based global healthcare platform synergizing biotech, medical devices, and AI.
Vyome Holdings, Inc.
Nasdaq: HIND
PRINCIPAL OFFICE
Harvard Square, One Mifflin Place, Suite 400, Cambridge, MA 02138
PHONE
+1 973-832-8147
SUBSIDIARIES
Vyome Therapeutics, Inc.
OFFICE
Harvard Square, One Mifflin Place, Suite 400, Cambridge, MA 02138
Vyome Therapeutics Limited, Subsidiary of Vyome Therapeutics, Inc.
OFFICE
Plot No. 465, Ground Floor, F.I.E., Patparganj Industrial Area, Delhi, India- 110092.
PHONE
+91-99682-17333
*Certain statements on this site are forward-looking within the meaning of federal securities laws. Please see our full disclaimer here.